Technology Partnerships

BioInvent has entered into several partnerships around the development and manufacturing of antibodies.

Antibody development partnerships typically involve BioInvent utilising its proprietary n-CoDeR^® technology to identify antibodies that can bind to partners' selected targets. Selected antibodies are further developed either by the partner alone or as part of a continued collaboration with BioInvent. BioInvent receives milestone payments and royalties on sales from these projects. Partners to date include Bayer, UCB-Celltech and XOMA.

Bayer HealthCare (www.bayer.co.uk)
Discovery and development of antibody products using the n-CoDeR^® library. The agreement allows for up to 14 therapeutic antibody products to be developed.

Mitsubishi Tanabe (www.mt-pharma.co.jp)
Discovery and development of antibody products using the n-CoDeR^® library. The agreement allows for up to five therapeutic antibody products to be developed.

UCB-Celltech (originally Oxford Glycosciences www.ucb.com)
A multiyear collaboration to develop and commercialise antibody drugs discovered using the n-CoDeR^® library.

XOMA (www.xoma.com)
Cross-license agreement for antibody related technologies, including the n-CoDeR^® platform.

BioInvent uses its knowledge and capabilities in antibody manufacturing to provide both clinical material and commercial products to clients. Our experience includes working with high-profile companies.

Examples of some of the companies that BioInvent works with are given below:

Sanofi-aventis (www.sanofi-aventis.co.uk)
Manufacturing clinical material.

ImmunoGen Inc (www.immunogen.com)
Manufacturing clinical material.

Alk Abelló (www.alk-abello.com)
Manufacturing a commercial diagnostic product.